2025 Adult Obesity Guidelines: Modern Care & GLP-1 Use
Modern clinical practice recognizes obesity as a complex, relapsing neurohormonal disease. Consequently, effective adult obesity management requires evidence-based and compassionate clinical strategies. The updated 2025 clinical practice guidelines from the U.S. Department of Veterans Affairs and Department of Defense emphasize comprehensive, lifelong care. Furthermore, these recommendations guide clinicians in delivering timely, individualized interventions across primary care settings.
Core Principles of Adult Obesity Management
First, clinicians must establish comprehensive lifestyle intervention as the cornerstone of therapy. This approach combines structured behavioral strategies, personalized nutrition, and regular physical activity. However, clinicians should not delay pharmacotherapy simply to enforce a trial of lifestyle modifications alone. In addition, healthcare teams must integrate medical therapies flexibly based on patient goals. Most importantly, providers must avoid discontinuing effective anti-obesity medications, because stopping therapy frequently triggers weight regain.
Screening Thresholds and Risk Assessment
Routine screening remains vital for identifying individuals at metabolic risk. Specifically, guidelines suggest screening adults with a body mass index of 25 kg/m² or higher. For Asian adults, clinicians should use a lower threshold of 23 kg/m² due to elevated visceral adiposity. Additionally, clinicians should assess waist circumference alongside broader clinical context to refine individual cardiometabolic risk. Therefore, evaluating overall functional status helps tailor therapeutic decisions effectively.
Pharmacotherapy and Surgical Interventions
Recent advances highlight the expanding role of potent pharmacotherapy. Specifically, glucagon-like peptide-1 receptor agonists provide significant benefits for weight loss and glycemic control. Clinicians should especially consider these patients who require advanced guidance through a certification course in diabetes and metabolic disorder care for prediabetes or type 2 diabetes. Furthermore, the guideline supports endoscopic sleeve gastroplasty as an emerging therapeutic option. Finally, metabolic and bariatric surgery eligibility extends to patients with severe obesity to ensure durable health outcomes.
Frequently Asked Questions
Q1: What are the screening thresholds for adult obesity management in Asian populations?
Clinicians should screen Asian adults at a body mass index cutoff of 23 kg/m² or higher. This lower threshold accurately identifies elevated cardiometabolic risk associated with visceral adiposity.
Q2: Should clinicians stop anti-obesity medications once patients reach their weight goal?
No, guidelines strongly discourage routinely discontinuing effective anti-obesity medications. Because obesity is a chronic relapsing disease, stopping pharmacotherapy often leads to significant weight regain.
Q3: Is completing a lifestyle intervention required before starting pharmacotherapy?
No, there is no requirement to complete or fail lifestyle interventions before initiating pharmacotherapy. Instead, clinicians can integrate medical treatments alongside lifestyle counseling from the start, a concept central to modern general practice.
References
- Corrado RL et al. Adult Overweight and Obesity Management: Updates From the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Ann Intern Med. 2026 Aug 25. doi: 10.7326/ANNALS-26-00676. PMID: 42636450.
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. Geneva: World Health Organization; 2025.
- Endocrine Society of India. ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India – An Update. Indian J Endocrinol Metab. 2025;29(4):315-330.
